Logo

Amgen and UCB's Evenity (Romosozumab) Receive CHMP Positive Opinion to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

Share this

Amgen and UCB's Evenity (Romosozumab) Receive CHMP Positive Opinion to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

Shots:

  • The EMA’s CHMP has adopted a positive opinion recommending marketing authorization for Evenity (romosozumab) based on P-III global studies including FRAME- ARCH and BRIDGE studies assessing Evenity vs PBO and active comparator in ~11-000 postmenopausal women with osteoporosis at high risk of fracture and with no history of MI or stroke
  • The CHMP’s recommendation will be reviewed by EC to approve therapy in Europe with its anticipated decision by the year-end 2019  
  • Evenity is a bone-forming mAb- act by inhibiting the activity of sclerostin thus resulted in increased bone formation and to a lesser extent decreased bone resorption and is an approved therapy in the US & Japan- South Korea for the treatment  of osteoporosis in women & women and men at high risk for fracture respectively

Click here to­ read full press release/ article | Ref: Amgen | Image: PM Live


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions